华大基因(300676) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥673,146,189.76, representing a year-on-year growth of 20.54%[7] - Net profit attributable to shareholders was ¥112,414,476.26, a decrease of 7.38% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥99,402,395.34, down 2.09% year-on-year[7] - Basic earnings per share for the reporting period was ¥0.28, a decline of 9.68% compared to the same period last year[7] - The weighted average return on net assets was 2.63%, a decrease of 0.54% compared to the previous year[7] - The net profit for the year-to-date period was ¥320,160,231.88, reflecting a growth of 2.48% compared to the same period last year[7] - Total operating revenue for Q3 2018 reached CNY 673,146,189.76, an increase of 20.5% compared to CNY 558,460,020.50 in the same period last year[42] - Net profit for the period was CNY 121,511,411.15, a decrease of 7.7% from CNY 131,762,643.99 in Q3 2017[44] - Total operating revenue for the period reached ¥79,246,901.31, a significant increase from ¥32,801,065.59 in the previous period, representing a growth of approximately 141.5%[47] - Net profit for the period was ¥18,502,616.50, compared to ¥6,569,037.58 in the same period last year, indicating a year-over-year increase of about 182.5%[48] Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,321,490,454, an increase of 4.10% compared to the end of the previous year[7] - The company’s total assets decreased to CNY 5,700,031,795.90 from CNY 5,992,195,589.52 at the beginning of the year[41] - The company’s total liabilities included accounts payable of 174,905,423.41 RMB, an increase from 119,658,078.74 RMB[36] - The total liabilities rose to CNY 909,061,278.26, compared to CNY 853,878,299.55 in the previous quarter[40] - The company’s equity attributable to shareholders increased to CNY 4,289,839,917.39 from CNY 4,148,624,622.62[40] Cash Flow - The company reported a net cash flow from operating activities of -¥154,789,954.44, a significant decrease of 293.90%[7] - Cash flow from operating activities decreased by 293.90% to -CNY 154,789,954.44, attributed to increased cash payments for goods and services[23] - Cash flow from investing activities improved to CNY 353,359,976.11, primarily due to the redemption of financial products[23] - The company reported a net cash flow from financing activities of -210,051,176.25 RMB, a decrease of 156.26% compared to the previous year[24] - The company generated cash inflows from operating activities totaling ¥1,462,810,857.64, compared to ¥1,241,390,081.32 in the previous period, representing an increase of approximately 17.8%[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 47,525[11] - The largest shareholder, Shenzhen BGI Technology Co., Ltd., held 37.18% of the shares, totaling 148,773,893 shares[11] - The company has a diverse shareholder base, with multiple investment partnerships involved[15] - The report indicates a stable shareholding structure with no significant changes in major shareholders during the reporting period[13] Research and Development - R&D expenses increased by 45.18% to CNY 161,135,347.68 due to higher investment in research projects[23] - Research and development expenses for the quarter were CNY 60,808,727.93, an increase of 52.0% from CNY 40,039,155.07 in the same quarter last year[42] - Research and development expenses increased to ¥43,252,190.72 from ¥37,174,626.09, marking a rise of approximately 16.5%[55] Inventory and Receivables - Accounts receivable increased by 50.06% to CNY 1,242,623,288.81 due to expanded sales volume[23] - Prepayments surged by 411.95% to CNY 242,715,034.63, primarily due to increased material prepayments[23] - Inventory rose by 48.31% to CNY 205,532,991.74, reflecting expanded sales and increased raw material reserves[23] - Other receivables rose by 149.16% to CNY 37,049,111.84, mainly due to increased bid guarantee deposits[23] Comprehensive Income - Total comprehensive income for the period was ¥148,002,882.28, compared to ¥131,866,156.91 in the previous period, an increase of approximately 12.2%[49] - Other comprehensive income after tax for the period was CNY 26,491,471.13, compared to CNY 103,512.92 in Q3 2017[44] - The company’s other comprehensive income after tax was ¥21,555,959.25, compared to a loss of ¥1,591,791.67 in the previous period, indicating a significant recovery[52] Dividend Information - The company distributed cash dividends of 80,020,000.00 RMB, with a payout of 2.00 RMB per 10 shares[28] - The company’s retained earnings as of September 30, 2018, were 95,660,686.10 RMB, carried forward for future distribution[28] Other Financial Metrics - The company reported a total operating cost of ¥1,475,169,578.09, up from ¥1,096,653,196.93, reflecting an increase of approximately 34.5%[51] - The total profit amounted to ¥224,346,484.00, up from ¥123,857,020.20, reflecting a growth of approximately 81%[56] - The total assets impairment loss was reported at ¥52,343,032.28, compared to ¥27,319,788.56 in the previous period, an increase of approximately 91.9%[52]